If they can generate revenue short-term with Covid then it is worth a try given the recent peer-reviewed papers. Who knows maybe it will give us a position of strength in negotiations going forward.

Investalot, if apabetalone is FDA approved as a Covid therapeutic there will be no need for BP negotiations, imo.   Literally billions of dollars will immediately flood into the company from bulk sales to countries around the world.  BOM2 and a dozen more trials if we want will therefore be independently pre-funded from overwhelming cashflow.

And I agree that the biggest threat to this scenario is Pfizer's neck-breaking speed vs. our glacial MO.